[go: up one dir, main page]

WO2013117751A3 - Méthodes liées au traitement des maladies inflammatoires - Google Patents

Méthodes liées au traitement des maladies inflammatoires Download PDF

Info

Publication number
WO2013117751A3
WO2013117751A3 PCT/EP2013/052629 EP2013052629W WO2013117751A3 WO 2013117751 A3 WO2013117751 A3 WO 2013117751A3 EP 2013052629 W EP2013052629 W EP 2013052629W WO 2013117751 A3 WO2013117751 A3 WO 2013117751A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
treatment
inflammatory diseases
methods related
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/052629
Other languages
English (en)
Other versions
WO2013117751A2 (fr
Inventor
Klaus Steensgaard FREDERIKSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to KR1020147022156A priority Critical patent/KR20140124767A/ko
Priority to CA2864133A priority patent/CA2864133A1/fr
Priority to BR112014019274A priority patent/BR112014019274A2/pt
Priority to MX2014009490A priority patent/MX2014009490A/es
Priority to AU2013217940A priority patent/AU2013217940A1/en
Priority to CN201380019432.0A priority patent/CN104204230A/zh
Priority to EP13704081.2A priority patent/EP2812445A2/fr
Publication of WO2013117751A2 publication Critical patent/WO2013117751A2/fr
Publication of WO2013117751A3 publication Critical patent/WO2013117751A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne des marqueurs génétiques associés avec une méthode de prédiction de la réponse clinique à un traitement anti-inflammatoire chez un patient souffrant d'une maladie inflammatoire.
PCT/EP2013/052629 2012-02-10 2013-02-11 Méthodes liées au traitement des maladies inflammatoires Ceased WO2013117751A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020147022156A KR20140124767A (ko) 2012-02-10 2013-02-11 염증성 질환 및 장애의 치료에 관한 방법
CA2864133A CA2864133A1 (fr) 2012-02-10 2013-02-11 Methodes liees au traitement des maladies inflammatoires
BR112014019274A BR112014019274A2 (pt) 2012-02-10 2013-02-11 métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
MX2014009490A MX2014009490A (es) 2012-02-10 2013-02-11 Metodos relacionados con el tratamiento de enfermedades y trastornos inflamatorios.
AU2013217940A AU2013217940A1 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders
CN201380019432.0A CN104204230A (zh) 2012-02-10 2013-02-11 治疗炎性疾病和病症的相关方法
EP13704081.2A EP2812445A2 (fr) 2012-02-10 2013-02-11 Méthodes liées au traitement des maladies inflammatoires

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12154917.4 2012-02-10
EP12154917 2012-02-10
US201261597924P 2012-02-13 2012-02-13
US61/597,924 2012-02-13

Publications (2)

Publication Number Publication Date
WO2013117751A2 WO2013117751A2 (fr) 2013-08-15
WO2013117751A3 true WO2013117751A3 (fr) 2013-10-03

Family

ID=48948117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052629 Ceased WO2013117751A2 (fr) 2012-02-10 2013-02-11 Méthodes liées au traitement des maladies inflammatoires

Country Status (8)

Country Link
EP (1) EP2812445A2 (fr)
KR (1) KR20140124767A (fr)
CN (1) CN104204230A (fr)
AU (1) AU2013217940A1 (fr)
BR (1) BR112014019274A2 (fr)
CA (1) CA2864133A1 (fr)
MX (1) MX2014009490A (fr)
WO (1) WO2013117751A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102481305B1 (ko) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006858A2 (fr) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Methode de traitement de maladies cardio-vasculaires et du metabolisme et detection des risques associes
WO2008048986A2 (fr) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Technique par batterie de gènes pour prédire la réponse dans les maladies intestinales inflammatoires
WO2008104608A1 (fr) * 2007-03-01 2008-09-04 Universite Catholique De Louvain Procédé pour la détermination et la classification de conditions rhumatismales
WO2008157282A1 (fr) * 2007-06-18 2008-12-24 Genentech, Inc. Marqueurs biologiques prédictifs d'une réponse d'arthrite rhumatoïde à des antagonistes de cellule b
WO2010113096A1 (fr) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Méthodes pour prévoir l'évolution clinique de la sclérose en plaque et la traiter
US20110091457A1 (en) * 2009-10-16 2011-04-21 Cornelis Lammert Verweij Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy
WO2011154139A2 (fr) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Marqueurs d'expression génique pour la prédiction d'une réponse à un traitement par un médicament anticorps monoclonal inhibant le récepteur de l'interleukine-6

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045261A2 (fr) 1999-12-07 2001-06-21 Parthus Technologies Plc Modele pour boucle a phase asservie a pompe a charge
EP1616575B1 (fr) 1999-12-23 2012-06-06 ZymoGenetics, Inc. Methode destinée à traiter l'inflammation
DE10227527A1 (de) 2002-06-20 2004-01-08 Clariant Gmbh Verfahren zur Herstellung von Disazopigmenten
US7435800B2 (en) 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
WO2005052000A2 (fr) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps et partenaires de liaison anti-il 20 et procedes d'utilisation dans l'inflammation
IES20050495A2 (en) 2005-07-20 2006-11-01 Minroc Techn Promotions Ltd A drill bit assembly for fluid-operated percussion drill tools
WO2007038501A2 (fr) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Marqueurs de l'arthrite rhumatoide
WO2007081465A2 (fr) 2005-12-09 2007-07-19 Chi-Mei Medical Center Anticorps dirigés contre l'interleukine 20 et procédé d'inhibition de la prolifération cellulaire induite par l'interleukine 20
EP1857559A1 (fr) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de prédiction de la réponse aux agents de blocage de TNF aplha
CA2668955A1 (fr) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede permettant de predire la sensibilite therapeutique a des agents bloquant le tnf-alpha
WO2008132176A2 (fr) 2007-04-27 2008-11-06 Universite Catholique De Louvain Méthode de prévision de la réponse d'un patient à une thérapie bloquant le tnf
KR20100037590A (ko) 2007-06-08 2010-04-09 바이오겐 아이덱 엠에이 인코포레이티드 항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커
CA2728685A1 (fr) 2008-06-30 2010-01-07 Novo Nordisk A/S Anticorps anti-interleukine-20 humaine
EP2337799A2 (fr) 2008-08-28 2011-06-29 Wyeth LLC Utilisations de cytokines des familles il-22, il-17, et il-1 dans les maladies auto-immunes
CA2752648A1 (fr) 2009-03-05 2010-09-10 Abbott Laboratories Proteines de liaison a il-17
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006858A2 (fr) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Methode de traitement de maladies cardio-vasculaires et du metabolisme et detection des risques associes
WO2008048986A2 (fr) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Technique par batterie de gènes pour prédire la réponse dans les maladies intestinales inflammatoires
WO2008104608A1 (fr) * 2007-03-01 2008-09-04 Universite Catholique De Louvain Procédé pour la détermination et la classification de conditions rhumatismales
WO2008157282A1 (fr) * 2007-06-18 2008-12-24 Genentech, Inc. Marqueurs biologiques prédictifs d'une réponse d'arthrite rhumatoïde à des antagonistes de cellule b
WO2010113096A1 (fr) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Méthodes pour prévoir l'évolution clinique de la sclérose en plaque et la traiter
US20110091457A1 (en) * 2009-10-16 2011-04-21 Cornelis Lammert Verweij Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy
WO2011154139A2 (fr) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Marqueurs d'expression génique pour la prédiction d'une réponse à un traitement par un médicament anticorps monoclonal inhibant le récepteur de l'interleukine-6

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JULIÀ ANTONIO ET AL: "Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells", PHARMACOGENOMICS, FUTURE MEDICINE LTD, UK, vol. 10, no. 10, 1 October 2009 (2009-10-01), pages 1697 - 1708, XP009160425, ISSN: 1744-8042 *
LEQUERRÉ THIERRY ET AL: "Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 4, 3 July 2006 (2006-07-03), pages R105, XP021020585, ISSN: 1478-6354, DOI: 10.1186/AR1924 *
NAKADA S ET AL: "Identification of candidate genes involved in endogenous protection mechanisms against acute pancreatitis in mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 391, no. 3, 15 January 2010 (2010-01-15), pages 1342 - 1347, XP026854448, ISSN: 0006-291X, [retrieved on 20100114], DOI: 10.1016/J.BBRC.2009.12.047 *
SARCHIELLI P ET AL: "Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 435, no. 3, 25 April 2008 (2008-04-25), pages 223 - 228, XP022655800, ISSN: 0304-3940, [retrieved on 20080226], DOI: 10.1016/J.NEULET.2008.02.040 *
SEKIGUCHI N ET AL: "Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 47, no. 6, 1 June 2008 (2008-06-01), pages 780 - 788, XP002562468, ISSN: 1462-0324, DOI: 10.1093/RHEUMATOLOGY/KEN083 *
SIRPA LEIVO-KORPELA ET AL: "Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma", JOURNAL OF INFLAMMATION, vol. 8, no. 1, 1 January 2011 (2011-01-01), pages 12, XP055030042, ISSN: 1476-9255, DOI: 10.1186/1476-9255-8-12 *
TANINO M ET AL: "Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 387, no. 2, 18 September 2009 (2009-09-18), pages 261 - 265, XP026434615, ISSN: 0006-291X, [retrieved on 20090703], DOI: 10.1016/J.BBRC.2009.06.149 *

Also Published As

Publication number Publication date
WO2013117751A2 (fr) 2013-08-15
CA2864133A1 (fr) 2013-08-15
CN104204230A (zh) 2014-12-10
AU2013217940A1 (en) 2014-07-31
EP2812445A2 (fr) 2014-12-17
MX2014009490A (es) 2014-08-29
BR112014019274A2 (pt) 2017-06-27
KR20140124767A (ko) 2014-10-27

Similar Documents

Publication Publication Date Title
WO2012149299A3 (fr) Procédés de traitement du cancer et de maladies inflammatoires au moyen de céréblon en tant que prédicteur
EP2710370A4 (fr) Méthodes de diagnostic et de traitement de maladies ou affections pulmonaires
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
LT2796132T (lt) Neurologinių sutrikimų terapija baklofeno ir akamprosato pagrindu
ZA201504484B (en) Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TWI560200B (en) Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
LT2726511T (lt) Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
EP2621499A4 (fr) Méthodes de traitement de maladies allergiques
WO2011140517A9 (fr) Méthodes de traitement de maladies pulmonaires
WO2014004990A3 (fr) Procédés pour déterminer l'efficacité d'un médicament en utilisant des protéines associées au céréblon
WO2014055790A9 (fr) Procédés et processus d'évaluation non invasive de variations génétiques
EP2663653A2 (fr) Méthodes de diagnostic et de traitement de troubles liés à la longueur de l' il
WO2014200952A3 (fr) Marqueurs génétiques de la réponse aux antipsychotiques
EP3039431A4 (fr) Procédé d'identification de biomarqueurs de maladies neurologiques et diagnostic des maladies neurologiques
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HUE036248T2 (hu) Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére
WO2013023059A3 (fr) Méthodes et compositions pour le traitement de maladies auto-immunes et inflammatoires
IL232710B (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
EP3052137A4 (fr) Procédés utilisant fndc5 pour identifier, évaluer, prévenir et traiter des troubles et des maladies neurologiques
IL238415A0 (en) Compositions and methods for treating or preventing diseases or disorders associated with eif4e dysregulation
WO2013117751A3 (fr) Méthodes liées au traitement des maladies inflammatoires
WO2011143557A3 (fr) Ttc humanisé et procédés d'utilisation associés
HK1250176A1 (zh) 用於确定细胞疗法的临床反应的生物标志物
WO2011139368A3 (fr) Méthodes de traitement d'une maladie inflammatoire
WO2012166659A3 (fr) Anticorps anti-emr1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13704081

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2013704081

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013217940

Country of ref document: AU

Date of ref document: 20130211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/009490

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147022156

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2864133

Country of ref document: CA

Ref document number: 2014556088

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014135733

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014019274

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014019274

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140805